308 related articles for article (PubMed ID: 16361247)
1. Elimination of abnormal sialylglycoproteins in fibroblasts with sialidosis and galactosialidosis by normal gene transfer and enzyme replacement.
Oheda Y; Kotani M; Murata M; Sakuraba H; Kadota Y; Tatano Y; Kuwahara J; Itoh K
Glycobiology; 2006 Apr; 16(4):271-80. PubMed ID: 16361247
[TBL] [Abstract][Full Text] [Related]
2. Short-term, high dose enzyme replacement therapy in sialidosis mice.
Wang D; Bonten EJ; Yogalingam G; Mann L; d'Azzo A
Mol Genet Metab; 2005 Jul; 85(3):181-9. PubMed ID: 15979029
[TBL] [Abstract][Full Text] [Related]
3. [Orientation of three lysosomal enzymes in the mouse inner ear and hearing loss in enzyme gene deficiency].
Guo YK; Xie DH; Yang XM
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Feb; 31(1):79-84. PubMed ID: 16562682
[TBL] [Abstract][Full Text] [Related]
4. New mutations in the PPBG gene lead to loss of PPCA protein which affects the level of the beta-galactosidase/neuraminidase complex and the EBP-receptor.
Malvagia S; Morrone A; Caciotti A; Bardelli T; d'Azzo A; Ancora G; Zammarchi E; Donati MA
Mol Genet Metab; 2004 May; 82(1):48-55. PubMed ID: 15110321
[TBL] [Abstract][Full Text] [Related]
5. Cytochemical and biochemical detection of intracellularly accumulated sialyl glycoconjugates in sialidosis and galactosialidosis fibroblasts with Macckia amurensis.
Kotani M; Yamada H; Sakuraba H
Clin Chim Acta; 2004 Jun; 344(1-2):131-5. PubMed ID: 15149881
[TBL] [Abstract][Full Text] [Related]
6. Transport of human lysosomal neuraminidase to mature lysosomes requires protective protein/cathepsin A.
van der Spoel A; Bonten E; d'Azzo A
EMBO J; 1998 Mar; 17(6):1588-97. PubMed ID: 9501080
[TBL] [Abstract][Full Text] [Related]
7. Targeting macrophages with baculovirus-produced lysosomal enzymes: implications for enzyme replacement therapy of the glycoprotein storage disorder galactosialidosis.
Bonten EJ; Wang D; Toy JN; Mann L; Mignardot A; Yogalingam G; D'Azzo A
FASEB J; 2004 Jun; 18(9):971-3. PubMed ID: 15084520
[TBL] [Abstract][Full Text] [Related]
8. Exclusion of NEU1 and PPGB from candidate genes for a lysosomal storage disease in Japanese Black cattle.
Masoudi AA; Yamato O; Yoneda K; Tsuji T; Mikami O; Kunieda T
Anim Sci J; 2009 Oct; 80(5):611-5. PubMed ID: 20163628
[TBL] [Abstract][Full Text] [Related]
9. Molecular pathology of NEU1 gene in sialidosis.
Seyrantepe V; Poupetova H; Froissart R; Zabot MT; Maire I; Pshezhetsky AV
Hum Mutat; 2003 Nov; 22(5):343-52. PubMed ID: 14517945
[TBL] [Abstract][Full Text] [Related]
10. Elastogenesis in cultured dermal fibroblasts from patients with lysosomal beta-galactosidase, protective protein/cathepsin A and neuraminidase-1 deficiencies.
Tatano Y; Takeuchi N; Kuwahara J; Sakuraba H; Takahashi T; Takada G; Itoh K
J Med Invest; 2006 Feb; 53(1-2):103-12. PubMed ID: 16538002
[TBL] [Abstract][Full Text] [Related]
11. Enzymatic activity of lysosomal carboxypeptidase (cathepsin) A is required for proper elastic fiber formation and inactivation of endothelin-1.
Seyrantepe V; Hinek A; Peng J; Fedjaev M; Ernest S; Kadota Y; Canuel M; Itoh K; Morales CR; Lavoie J; Tremblay J; Pshezhetsky AV
Circulation; 2008 Apr; 117(15):1973-81. PubMed ID: 18391110
[TBL] [Abstract][Full Text] [Related]
12. Stable expression of protective protein/cathepsin A-green fluorescent protein fusion genes in a fibroblastic cell line from a galactosialidosis patient. Model system for revealing the intracellular transport of normal and mutated lysosomal enzymes.
Naganawa Y; Itoh K; Shimmoto M; Kamei S; Takiguchi K; Doi H; Sakuraba H
Biochem J; 1999 Jun; 340 ( Pt 2)(Pt 2):467-74. PubMed ID: 10333491
[TBL] [Abstract][Full Text] [Related]
13. Intermittent enzyme replacement therapy with recombinant human β-galactosidase prevents neuraminidase 1 deficiency.
Luu AR; Wong C; Agrawal V; Wise N; Handyside B; Lo MJ; Pacheco G; Felix JB; Giaramita A; d'Azzo A; Vincelette J; Bullens S; Bunting S; Christianson TM; Hague CM; LeBowitz JH; Yogalingam G
J Biol Chem; 2020 Sep; 295(39):13556-13569. PubMed ID: 32727849
[TBL] [Abstract][Full Text] [Related]
14. Heterodimerization of the sialidase NEU1 with the chaperone protective protein/cathepsin A prevents its premature oligomerization.
Bonten EJ; Campos Y; Zaitsev V; Nourse A; Waddell B; Lewis W; Taylor G; d'Azzo A
J Biol Chem; 2009 Oct; 284(41):28430-28441. PubMed ID: 19666471
[TBL] [Abstract][Full Text] [Related]
15. Chaperone-mediated gene therapy with recombinant AAV-PPCA in a new mouse model of type I sialidosis.
Bonten EJ; Yogalingam G; Hu H; Gomero E; van de Vlekkert D; d'Azzo A
Biochim Biophys Acta; 2013 Oct; 1832(10):1784-92. PubMed ID: 23770387
[TBL] [Abstract][Full Text] [Related]
16. Biochemical and molecular characterization of novel mutations in GLB1 and NEU1 in patient cells with lysosomal storage disorders.
Kwak JE; Son MY; Son YS; Son MJ; Cho YS
Biochem Biophys Res Commun; 2015 Feb; 457(4):554-60. PubMed ID: 25600812
[TBL] [Abstract][Full Text] [Related]
17. Neu4, a novel human lysosomal lumen sialidase, confers normal phenotype to sialidosis and galactosialidosis cells.
Seyrantepe V; Landry K; Trudel S; Hassan JA; Morales CR; Pshezhetsky AV
J Biol Chem; 2004 Aug; 279(35):37021-9. PubMed ID: 15213228
[TBL] [Abstract][Full Text] [Related]
18. Role of beta-galactosidase and elastin binding protein in lysosomal and nonlysosomal complexes of patients with GM1-gangliosidosis.
Caciotti A; Donati MA; Boneh A; d'Azzo A; Federico A; Parini R; Antuzzi D; Bardelli T; Nosi D; Kimonis V; Zammarchi E; Morrone A
Hum Mutat; 2005 Mar; 25(3):285-92. PubMed ID: 15714521
[TBL] [Abstract][Full Text] [Related]
19. Lysosomal sialidase NEU1, its intracellular properties, deficiency, and use as a therapeutic agent.
Itoh K; Tsukimoto J
Glycoconj J; 2023 Dec; 40(6):611-619. PubMed ID: 38147151
[TBL] [Abstract][Full Text] [Related]
20. Identification of a CTL4/Neu1 fusion transcript in a sialidosis patient.
Uhl J; Penzel R; Sergi C; Kopitz J; Otto HF; Cantz M
FEBS Lett; 2002 Jun; 521(1-3):19-23. PubMed ID: 12067718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
